IPF Catalyst Challenge

February 15, 2018February 15, 2018

NICE Opinion Limiting Esbriet to UK Patients with Moderate to Severe IPF Disappoints, patientMpower Says

The digital healthcare company patientMpower expressed disappointment at the opinion issued by an influential U.K. healthcare advisory group to limit the use of Esbriet (pirfenidone, marketed by Genentech) to patients with moderate to ... Read more

January 26, 2018January 26, 2018

Three Winners Will Share $1 Million for Innovation in IPF Catalyst Challenge

Idiopathic Pulmonary Fibrosis, News

Three companies will equally share $1 million for winning the IPF Catalyst Challenge, a competition that fosters innovative solutions for helping idiopathic pulmonary fibrosis (IPF) patients. The winners are Advanced Interactive Response Systems ... Read more

January 24, 2018January 24, 2018

Finalists for $1 million IPF Catalyst Challenge Includes patientMpower

Idiopathic Pulmonary Fibrosis, News

PatientMpower is one of the selected finalists of the IPF Catalyst Challenge to receive $1 million to fund research into idiopathic pulmonary fibrosis (IPF). The IPF Catalyst Challenge, being held ... Read more

January 15, 2018January 15, 2018

Owlstone Medical Among Finalists in IPF Catalyst Challenge

Idiopathic Pulmonary Fibrosis

Owlstone Medical is a finalist in the IPF Catalyst Challenge competition for $1 million in funding for advanced idiopathic pulmonary fibrosis research. The Catalyst Challenge aims to engage worldwide entrepreneurs ... Read more

September 27, 2017September 27, 2017

Collaboration Will Raise IPF Awareness, Reward Best Ideas for Improving Quality of Life

News

The American Lung Association and Three Lakes Partners will collaborate to increase awareness about idiopathic pulmonary fibrosis (IPF) and reward big ideas to improve patients’ quality of life. The partnership was announced ... Read more

August 10, 2017August 10, 2017

Three Lakes Partners Now Accepting Submissions for $1M IPF Healthcare Challenge

Idiopathic Pulmonary Fibrosis, News

Three Lakes Partners, a philanthropic venture committed to end idiopathic pulmonary fibrosis (IPF), has officially launched its $1 million IPF Catalyst Challenge and is now accepting submissions. The healthcare competition will award ... Read more

May 3, 2017May 3, 2017

Three Lakes Partners and MATTER Announce $1M IPF Catalyst Challenge

Idiopathic Pulmonary Fibrosis, News

Three Lakes Partners and MATTER announced a $1 million IPF Catalyst Challenge to engage innovators, entrepreneurs and researchers to find solutions for idiopathic pulmonary fibrosis (IPF) patients’ greatest need – ... Read more